Research Excellence Award
Sara Garcia-Rates
Neuro Bio Ltd, United Kingdom
| Sara Garcia-Rates |
| Affiliation |
Neuro Bio Ltd |
| Country |
United Kingdom |
| Scopus ID |
23388862700 |
| Documents |
26 |
| Citations |
336 |
| h-index |
11 |
| Subject Area |
Neuroscience |
| Event |
Research Awards and Recognitions |
| ORCID |
0000-0002-1848-4811 |
Sara Garcia-Rates is a neuroscience researcher and biotechnology executive associated with Neuro Bio Ltd. With more than two decades of experience, her work focuses on neuroscience, neurodegenerative diseases, translational medicine, and biotechnology innovation. She has contributed to Alzheimer’s disease research through leadership in preclinical drug development, assay validation, intellectual property strategy, and scientific collaboration. Her academic background in pharmacology and biomedicine supports her role in advancing therapeutic development and translational research. Garcia-Rates combines scientific leadership with commercialization strategy, contributing to biomedical innovation and the development of novel approaches for neurodegenerative disease treatment.[1]
Abstract
Sara Garcia-Rates is a multidisciplinary neuroscience researcher specializing in neurodegenerative disease therapeutics, Alzheimer’s disease drug discovery, and translational biotechnology. Her work includes developing preclinical research strategies, expanding biotechnology patent portfolios, and advancing therapeutic candidates through international scientific collaborations. She has also contributed to neuropharmacology research focused on nicotinic receptor biology, neurotoxicity mechanisms, and receptor-mediated signaling pathways, establishing a strong profile in neuroscience innovation and therapeutic development.[2]
Keywords
Neuroscience, Alzheimer’s disease, neuropharmacology, biotechnology, translational medicine, preclinical development, nicotinic receptors, neurodegeneration, therapeutics, pharmacology, biotechnology leadership, drug discovery, intellectual property, neuroscience innovation.
Introduction
Sara Garcia-Rates has built an interdisciplinary research profile combining neuroscience, biotechnology, and translational medicine. Her work focuses on neurodegenerative diseases, neuronal signaling, receptor modulation, and therapeutic development, alongside contributions to biotechnology management, patent development, research funding, and scientific collaborations.[3]
Sara Garcia-Rates received advanced training in biology, pharmacology, and biomedicine at the University of Barcelona and completed postdoctoral research at the University of Oxford Department of Pharmacology. Her career combines academic neuroscience research with biotechnology leadership, focusing on translational biomedical science and therapeutic innovation.[2]
Research Profile
Sara Garcia-Rates serves as Chief Scientific Officer at Neuro Bio Ltd, where she has contributed since 2013. Her work includes leading preclinical neuroscience research, therapeutic development, experimental assay design, and intellectual property strategy. [1]
Her leadership includes overseeing scientific projects, managing multidisciplinary teams, and coordinating collaborative partnerships. Under her direction, the organization expanded its patent portfolio from two patents to twenty-two patent families related to neurodegeneration, oncology, anti-aging research, and therapeutic technologies.[4]
Sara Garcia-Rates has also contributed to funding acquisition strategies, scientific advisory board activities, and partnerships with universities, contract research organizations, and industrial collaborators. These activities illustrate the integration of scientific research with translational commercialization and innovation management within the biotechnology sector.[5]
Research Contributions
Garcia-Rates has contributed to neuroscience research on nicotinic receptors, neurotoxicity, intracellular signaling, and the effects of methamphetamine and MDMA exposure. Her studies focus on receptor-mediated pathways, oxidative stress, and neurochemical regulation in experimental systems.[2]
Her translational research includes developing therapeutic candidates for Alzheimer’s disease at Neuro Bio Ltd. She contributed to the evaluation and optimization of nearly two hundred compounds, supporting the development of preclinical therapies and patent-protected technologies for neurodegenerative disorders.[4]
Additional contributions include establishment of research partnerships across the United Kingdom and international biotechnology networks. Her work in collaborative development has supported external scientific collaborations, intellectual property growth, and strategic development of biotechnology assets involving therapeutic and diagnostic innovation.[5]
- Leadership of Alzheimer’s disease therapeutic development programs.
- Expansion of biotechnology patent portfolios and translational research assets.
- Research on nicotinic receptor pharmacology and neurotoxicity.
- Coordination of interdisciplinary scientific collaborations and advisory activities.
- Management of preclinical neuroscience development programs.
Publications
Sara Garcia-Rates has published research in neuropharmacology, receptor biology, and neuroscience, focusing on neurotoxicity, nicotinic receptor regulation, intracellular signaling, and neurochemical mechanisms. Her work contributes to the understanding of receptor-mediated neurological disorders and includes both scientific journal articles and book chapters on methamphetamine- and MDMA-related neurotoxicity.[2]
- Garcia-Ratés S, Camarasa J, Escubedo E, Pubill D. Methamphetamine and 3,4-methylenedioxymethamphetamine interact with central nicotinic receptors and induce their upregulation. Toxicology and Applied Pharmacology, 2007.
- Chipana C, García-Ratés S, Camarasa J, Pubill D, Escubedo E. Different oxidative profile and nicotinic receptor interaction of amphetamine and MDMA. Neurochemistry International, 2008.
- Garcia-Ratés S, Camarasa J, Sánchez-García AI, Gandía L, Escubedo E, Pubill D. Effects of MDMA on nicotinic receptors and intracellular calcium increase. Toxicology and Applied Pharmacology, 2010.
- Pubill D, Garcia-Ratés S, Camarasa J, Escubedo E. Neuronal nicotinic receptors as new targets for amphetamine derivatives. Pharmaceuticals, 2011.
Research Impact
The research activities of Sara Garcia-Rates demonstrate impact across both academic neuroscience and biotechnology innovation. Her publication metrics include twenty-six indexed documents, more than three hundred citations, and an h-index of eleven, reflecting measurable scholarly engagement within the neuroscience research community.[1]
Garcia-Rates has contributed to biotechnology development through preclinical therapeutic research, patent expansion, and translational neuroscience projects focused on neurodegenerative diseases. She has also supported commercialization efforts, investment acquisition, and research funding to advance biotechnology innovation and organizational growth.[4]
Her scientific leadership has also included mentoring activities, partnership development with academic institutions, and participation in scientific advisory initiatives. These contributions indicate broader influence beyond publication metrics alone, extending into organizational development and interdisciplinary scientific collaboration.[5]
Award Suitability
Sara Garcia-Rates combines expertise in neuroscience research, translational biomedical science, and biotechnology leadership. Her work in therapeutic development, scientific publications, intellectual property expansion, and collaborative research reflects sustained contributions to neuroscience and biotechnology innovation.[3]
Her ability to lead multidisciplinary scientific projects and contribute to translational therapeutic development highlights her role in modern biomedical research. Her work in therapeutic innovation, patent expansion, and scientific collaboration demonstrates continued engagement in neuroscience research and biotechnology advancement.[4]
Conclusion
Sara Garcia-Rates has built a multidisciplinary career in neuroscience research, biotechnology leadership, and therapeutic development. Through her work at Neuro Bio Ltd and her scientific publications, she has contributed to neuropharmacology research, Alzheimer’s disease therapeutics, and biotechnology innovation.[5]
External Links
References
- Elsevier. (n.d.). Scopus author details: Sara Garcia-Rates, Author ID 23388862700. Scopus. https://www.scopus.com/authid/detail.uri?authorId=23388862700
- Garcia-Ratés S, Camarasa J, Escubedo E, Pubill D. (2007). Methamphetamine and 3,4-methylenedioxymethamphetamine interact with central nicotinic receptors and induce their upregulation. Toxicology and Applied Pharmacology. https://doi.org/10.1016/j.taap.2007.05.019
- Pubill D, Garcia-Ratés S, Camarasa J, Escubedo E. (2011). Neuronal nicotinic receptors as new targets for amphetamine derivatives. Pharmaceuticals. https://doi.org/10.3390/ph4060822
- Neuro Bio Ltd. (2025). Research development activities, patent portfolio expansion, and preclinical neuroscience initiatives.
- Awards and Recognitions. (n.d.). Research Awards and Recognitions official website. https://awardsandrecognitions.com/